New Delhi, Jan. 8 -- Panacea Bio's share price surged as much as 6% to Rs.407.60 apiece in Thursday's trading session after the company said it has completed enrolment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll.

"In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we are now delighted to inform you that enrollment of study participants in the context of DengiAll(R) Phase-III clinical trial has been completed (i.e., 10,335 study participants)," the company said in an exchange filing dated January 7.

The company has enrolled 10,335 participants in the late-stage clinical trial. Each subject will be followed for two years after ...